Immune monitoring (including standard immune status and leukemia-specific cell monitoring by ELISPOT and CSA + LAA stimulation) at defined timepoints showed (other than before treatment and in the patients with Kit M treatment) a decrease in DCs and in proliferating and Tnon-naive of the CD8 and CD4 lines. Here, CD8A is linked to leukemia.